Tissue CALB2 is clinically used to distinguish CALB2-positive epithelioid and mixed-type (biphasic) malignant mesothelioma (MM) from adenocarcinoma, while serum CALB2 could potentially serve as a predictive biomarker for poor survival and outcomes of cisplatin-based chemotherapy in MM [50]. Here, CALB2 is linked to Miyoshi myopathy.